Prostate cancer is the most common cancer in men in nearly two-thirds of the world. It ranks second globally, behind lung cancer, and is the fifth leading cause of cancer-related deaths, following stomach, liver, colorectal, and lung cancers. Worldwide, the number of prostate cancer cases are projected to double to 2.9 million new cases annually by 2040.

Shifting from advanced to early diagnosis of prostate cancer is crucial in ensuring timely and effective treatment, ultimately improving survival and quality of life. However, with this rising number of men presenting with suspected prostate cancer, efficient and accurate management strategies are vital to avoid unnecessary procedures while ensuring clinically significant cancers are detected and treated appropriately.

Challenge 1: Balancing early detection with the risk of overdiagnosis

As compared to late detection, early detection of prostate cancer has the potential to save lives and allow for less aggressive treatments.

However, many detected cancers are low-risk and may never progress, leading to unnecessary biopsies and overtreatment.

Challenge 2: Optimizing precision for targeted diagnosis and treatment

While multiparametric MRI (mpMRI) can reduce biopsy numbers, poor image quality remains a cause of overdiagnosis. Standard biopsy techniques often:

• Miss clinically significant tumors
• Misclassify cancer severity

This leads to:

• Repeat procedures
• Delayed treatment decisions
• Potential disease progression

Challenge 3: Reducing patient discomfort and biopsy burden

Patients are often reluctant to undergo multiple needle biopsies due to:

• Pain
• Side effects

This is especially problematic with conventional TRUS-guided methods, which require numerous samples.

Challenge 4: Managing provider workload

Conventional workflows are time-intensive, involving:

• Lengthy imaging procedures
• Manual interpretation of results

With rising caseloads, the increased demand for early detection risks overwhelming healthcare providers.